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Abstract 
Background: Tocilizumab blocks pro‑inflammatory activity of interleukin‑6 (IL‑6), involved in pathogenesis of pneu‑
monia the most frequent cause of death in COVID‑19 patients.
Methods: A multicenter, single‑arm, hypothesis‑driven trial was planned, according to a phase 2 design, to study the 
effect of tocilizumab on lethality rates at 14 and 30 days (co‑primary endpoints, a priori expected rates being 20 and 
35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accom‑
plished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multi‑
variable logistic regression model to assess prognostic variables on survival.
Results: In the primary intention‑to‑treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, 
and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6–24.0, P = 0.52) and 22.4% 
(97.5% CI: 17.2–28.3, P < 0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that 
included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regres‑
sion analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids 
was associated with greater survival. A statistically significant interaction was found between tocilizumab and respira‑
tory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory 
support at baseline.
Conclusions: Tocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxic‑
ity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.
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Background
Pneumonia is the most frequent and serious compli-
cation of COVID-19, due to excessive host immune 
response causing an acute respiratory distress syndrome 
[1–5].
Interleukin 6 (IL-6) is a pro-inflammatory cytokine 
implicated in several rheumatic diseases and in the so-
called cytokine release syndrome (CRS). Tocilizumab is 
a recombinant humanized monoclonal antibody, directed 
against the IL-6 receptor. It is indicated for treating 
severe rheumatoid arthritis, systemic juvenile idiopathic 
polyarthritis and severe cytokine release syndrome (CRS) 
induced by chimeric antigen receptor T-cells (CAR-T) [6, 
7].
Chinese researchers treated 21 patients with severe or 
critical COVID-19 pneumonia with tocilizumab 400 mg 
iv with efficacy in terms of reduction of oxygen require-
ment (15/20), resolution of radiologic lung lesions 
(19/21), normalization of lymphocyte count (10/19), and 
reduction of C-reactive protein levels (16/19) [8]. These 
results prompted a randomised trial (tocilizumab vs con-
trol, ChiCTR2000029765).
On March 19th, 2020 during the ascending phase of the 
Italian breakout, we launched the TOCIVID-19 study, to 
describe the efficacy of tocilizumab while controlling the 
highly increasing off-label use of the drug.
Methods
TOCIVID-19, an academic multicenter clinical trial, was 
promoted by the National Cancer Institute of Naples and 
was approved for all Italian centers by the National Ethi-
cal Committee at the Lazzaro Spallanzani Institute on 
March 18th, 2020; two amendments followed on March 
24th, 2020 and April 28th, 2020 [9]. The study is coordi-
nated through the web-based platform managed by the 
Clinical Trial Unit of the promoting center.
Study design
330 patients were initially planned for the single-arm 
phase 2 study based on one-month lethality rate of 15% 
as null hypothesis, an alternative hypothesis for tocili-
zumab of 7.5% (i.e. halving the expected lethality rate), 
99% power and 5% two-tailed alpha error. Taking into 
account about 20% of cases not eligible after registra-
tion 400 patients had to be enrolled. The initial calcula-
tion was based on March 10th daily report on Italian 
breakout, but data tumultuously accumulating between 
March 10th and April 15th clearly showed it was largely 
underestimated, and that adding an earlier outcome 
could be worthwhile. Thus, the April 24th amendment 
introduced 14-day lethality rate as co-primary endpoint, 
and the expected lethality rates (null-hypotheses) at 14 
and 30  days were redefined at 2 and 35%, respectively, 
based on data received from the Italian National Insti-
tute of Health [10]. Nonetheless we decided to leave the 
planned sample size unchanged since it still allowed 99% 
and 95% power to recognize 10% absolute reduction at 14 
and 30 days, respectively, with a significance level of 2.5% 
for each co-primary endpoint. It is worth emphasizing 
that any change in the protocol was introduced before 
extracting mortality data from the database, i.e. not being 
aware of the number and timing of recorded deaths.
Patients
Patients hospitalized due to clinical/instrumental signs 
of pneumonia, and with real-time PCR diagnosed SARS-
CoV-2 infection, were eligible for the phase 2 study if 
they had oxygen saturation at rest in ambient air ≤ 93% or 
required oxygen support or mechanical ventilation either 
non-invasive or invasive (intubated less than 24 h before 
registration). There was no limitation based on age and 
gender.
Patients were not eligible in case of known hypersen-
sitivity to tocilizumab, known active infections or other 
clinical conditions that could not be treated or solved 
according to the judgment of the clinician and contrain-
dicated tocilizumab, ALT/AST > 5 times the upper limit 
of the normality, neutrophils count < 500/mmc, plate-
lets < 50.000/mmc, bowel diverticulitis or perforation.
Informed consent for participation in the study could 
be oral if a written consent was unfeasible. However, if 
patients lack capacity to consent due to disease severity, 
and an authorized representative was not immediately 
available, treatment could be administered by the treat-
ing physician on her/his own responsibility.
Treatment
Tocilizumab was administered at the dose of 8  mg/kg 
up to a maximum of 800 mg per dose. Such dose is the 
same approved by FDA for the treatment of CRS follow-
ing CAR-T therapy [6]. A second administration of toci-
lizumab (same dose) was allowed 12 h after the first one 
if respiratory function had not recovered, at discretion of 
the Investigator. Tocilizumab was supplied at no cost by 
Roche Italy. Due to the rapidly increasing request, a vari-
able delay between the date of patient registration and 
Registration EudraCT (2020‑001110‑38); clinicaltrials.gov (NCT04317092).
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drug availability at the clinical centers occurred. There 
was no contraindication for concomitant treatment of 
respiratory impairment; also, concomitant experimental 
antiviral treatment was allowed.
Statistical analysis
Primary analysis was performed in the intention to treat 
population (ITT), defined as all patients enrolled; a sec-
ondary analysis was done in the modified ITT (mITT) 
population with patients who had received at least one 
dose of the study drug. All the subjects enrolled by unco-
operative centers, i.e. centers providing information on 
baseline characteristics and treatment for less than 25% 
of their patients, were removed from any analyses. This 
amendment, in agreement with IDMC, was made blind 
to outcome data, i.e. before extracting mortality data.
Statistical analysis is detailed elsewhere [10]. Briefly, 
differences between groups of baseline characteristics, 
collected at the time of registration, are assessed for cat-
egorical variables using χ2 test and for continuous vari-
ables using Wilcoxon rank-sum test. Patients discharged 
to home or low-intensity care setting are considered 
alive at the end-date of the follow-up period of 30 days. 
Exact 97.5% Clopper-Pearson confidence intervals (CI) 
are calculated for the proportions of death at 14 and 
30 days. Pre-specified null hypotheses at days 14 and 30 
are tested by a two-sided binomial test with alpha level 
equal to 0.025. Efficacy outcomes (with exact 95% CI) are 
described in baseline subgroups defined by demograph-
ics and clinical variables and compared with exact χ2 test. 
Analyses were carried out using Stata version 14.0 (Stata 
Corp. College Station, TX, USA) and R version 3.6.1 (R 
Foundation for Statistical Computing, Vienna, Austria).
Validation cohort
Since the number of patients planned in the single-arm 
phase 2 design was quickly achieved in less than 24 h, a 
second prospective cohort, involving eligible patients 
registered by participating centers in the five subsequent 
days, was added to the study to corroborate the main 
phase 2 findings. The analyses in this ‘validation’ cohort 
are to be considered secondary. The enrollment in the 
additional cohort was limited to five days because of 
the emerging drug shortage due to the huge request of 
drug by centers. The analyses performed in phase 2 were 
repeated in the validation cohort. For the sake of effi-
ciency, the results of the validation cohort are reported 
side by side those of phase 2.
Joint cohort for safety analysis
Analysis of safety was performed joining the two pro-
spective cohorts and was limited to patients who received 
at least one dose of the study drug. Adverse events 
recorded from registration up to 30  days were graded 
according to CTCAE term (Version 5.0) and reported for 
each category and term as the worst grade suffered by 
patients through the whole period of observation after 
treatment administration.
Exploratory multivariable analysis
An exploratory multivariable logistic regression model 
was also performed in the combined cohort to assess 
prognostic variables on survival, that involved treatment 
with tocilizumab and/or corticosteroids [11], age (≤ 60, 
61–70, > 70), gender, type of respiratory support (oxygen, 
non-invasive mechanical ventilation [NIMV], invasive 
mechanical ventilation [IMV]), PaO2/FiO2 ratio (≤ 100, 
101–200, > 200, missing/not evaluated), population 
(phase 2 or validation) and geographical area (Lombar-
dia, Veneto, Emilia-Romagna, other Northern regions, 
Center, South and Islands) as covariates. To reduce 
immortal time bias, patients who received tocilizumab 
four or more days after registration were excluded from 
the analysis. The interaction effects between treatment 
and the other covariates were tested in turn one at a time 
by Wald test and retained in the final model only if signif-
icant. Difference in the lethality rate between treated and 
untreated patients was calculated within specific sub-
groups and 95% CI was calculated by means of Agresti 
and Caffo method [11]. Description of such differences 
must be considered as exploratory and hypothesis-gener-
ating only.
Results
Single‑arm phase 2 cohort
From March 19th (at 14:00) to March 20th (at 12:45), 
2020, 51 centers prospectively registered 402 patients 
for the phase 2 study (Fig. 1, left side), of which 2 cases 
were duplicated and one case withdrew consent. Ninety-
eight patients enrolled by 12 uncooperative centers were 
removed from the analysis. Therefore, the phase 2 ITT 
population include 301 patients. Out of these, 21 were 
found ineligible a posteriori (12 intubated more than 
24 h before registration, 7 registered after being already 
treated, 2 with both violations) but remained in the 
analysis. Geographical distribution and baseline charac-
teristics of patients are summarized in Additional file 1: 
Figure S1 (top graphs), Table 1 (left side) and Additional 
file 1: Tables S1–3 (left side).
Due to lagged drug availability, treatment was given to 
59.8% of patients. Median time from registration to treat-
ment administration was 2 days; 23.3% of treated patients 
received tocilizumab four or more days after registra-
tion. The most frequent reason for not giving the drug 
(once available) was clinical improvement (Additional 
file 1: Table S4, left side). Patients who were younger, and 
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those with worse respiratory function were preferentially 
treated; also, the geographic location of the center played 
a role (Table 2, left side).
Overall, 67 (22.3%) deaths were reported in the ITT 
phase 2 cohort. Lethality rate was 18.4% (97.5% CI: 
13.6–24.0) at 14 days and 22.4% (97.5% CI: 17.2–28.3) at 
30 days. The null hypothesis was rejected at 30 days but 
not at 14  days (P < 0.001and P = 0.52, respectively). At 
both time points, lethality rates were lower in the mITT 
population (15.6% and 20.0%—Table 3, left side). Due to 
typical immortal time bias, lethality rates at 14 days were 
lower for patients receiving treatment four or more days 
after registration. Risk of death was significantly higher in 
patients older and with worse PaO2/FiO2 ratio; in addi-
tion, lethality rates were lower for patients receiving con-
current corticosteroids, particularly at 14 days where the 
difference was statistically significant (Fig.  2 and Addi-
tional file 1: Table S5, left side).
Single‑arm validation cohort
The validation cohort included 1273 patients enrolled by 
211 centers from March 20th to March 24th, 2020 (Fig. 1, 
right side). Three hundred fifty-three patients enrolled 
from 65 uncooperative centers were removed, and 920 
patients represented the ITT population. Baseline char-
acteristics, shown in tables and figures side by side those 
of phase 2 patients, were more favorable in the valida-
tion than in the phase 2 cohort. Treatment compliance 
was similar (Additional file 1: Table S4, right side). Also 
in the validation cohort, available treatment was prefer-
entially given to patients with worse respiratory func-
tion (Table  2, right side). Overall, 158 (17.2%) deaths 
were reported in the ITT validation cohort. Probability 
of death was lower in the validation than in the phase 2 
cohort, particularly among untreated patients (Addi-
tional file  1: Figure S2). In the validation cohort, lethal-
ity rates were consistently lower than the predefined 
null hypothesis both at 14 and 30 days in the ITT (11.4 
and 18.4%) and mITT (10.9% and 20.0%) populations 
(Table 3, right side). Subgroup analysis of lethality rates 
produced results similar to those seen in phase 2 (Addi-
tional file 1: Figure S3 and Table S5, right side).
Safety analysis
Safety analysis was done in 628/708 patients of the com-
bined cohort who had received at least one dose of toci-
lizumab (Additional file 1: Table S6). At least one adverse 
event was reported in 40.8% of patients. Of note, 68 
deaths (10.8%) were categorized within adverse events 
scale. Causality between such deaths and treatment was 
described as possible only in one of the 35 cases of res-
piratory failure. All the other fatal adverse events were 
Fig. 1 Study flow
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reported as unlikely or not related to treatment admin-
istration. Seven out of 8 fatal infections were specified as 
COVID pneumonia. Adverse events that may represent 
specific side effects of tocilizumab are allergic reactions 
[3 cases] and ALT or AST increase (reported in 10.5 
and 9.1%, respectively) that was severe (grade 3 or 4) in 
around 3% of cases.
Hypothesis‑generating multivariable analysis
Results of the exploratory multivariable logistic regres-
sion analysis in the combined cohort are reported in 
Additional file  1: Table  S7. Age and respiratory func-
tion measured by PaO2/FiO2 ratio were independently 
significant prognostic factors; the use of corticosteroids 
was associated with a lower OR of death both at 14 (OR 
0.36, 95% CI: 0.21–0.62) and at 30  days (OR 0.62, 95% 
CI: 0.40–0.95). No significant interaction was found 
between the effect of tocilizumab and age, gender, PaO2/
FiO2 ratio, geographic location and phase 2 vs valida-
tion cohorts; also, no interaction was found between the 
effect of tocilizumab and the use of corticosteroids. A 
significant interaction was found between treatment and 
required respiratory support, interaction test p-values 
being equal to 0.03 and 0.08 at 14 and 30  days, respec-
tively. Specifically, treatment effect on lethality rates was 
larger among patients not requiring mechanical respira-
tory support within 24  h from registration with a OR 
equal to 0.37 (95% CI: 0.18–0.74) and 0.50 (95% CI: 0.27–
0.92) and absolute reductions equal to 7.7 and 6.2%, at 14 
and 30 days, respectively (Additional file 1: Figure S4).
Discussion
The primary analysis of the single-arm phase 2 
TOCIVID-19 cohort suggests that tocilizumab may 
reduce lethality at 30 days, although its impact at 14 days 
seems less relevant. The adverse event profile is consist-
ent with other reports and did not generate clinically 
relevant warnings, possibly because of the severity of 
clinical symptoms related to the underlying pathologic 
condition. [12, 13] Interestingly, the exploratory multi-
variable analysis showed that the possible effect of toci-
lizumab might be greater among patients not requiring 
mechanical ventilation and might be independent of the 
effect of corticosteroids, that were associated with lower 
Table 1 Baseline characteristics of  patients in  the  ITT 
phase 2 and validation cohorts
ITT Phase 2 ITT Validation
N = 301 N = 920
Geographic area—no. (%)
 Lombardia 136 (45.2%) 346 (37.6%)
 Veneto 65 (21.6%) 41 (4.5%)
 Emilia Romagna 37 (12.3%) 142 (15.4%)
 Other Northern regions – 91 (9.9%)
 Center 39 (13.0%) 186 (20.2%)
 South and Islands 24 (8.0%) 114 (12.4%)
Age—no. (%)
  ≤ 60 122 (40.5%) 375 (40.8%)
 61–70 107 (35.5%) 263 (28.6%)
 71 + 72 (23.9%) 282 (30.7%)
Female sex—no. (%) 59 (19.6%) 200 (21.7%)
Ethnic group—no. (%)
 Caucasian 271 (97.1%) 853 (97.7%)
 Asiatic 3 (1.1%) 2 (0.2%)
 Other 5 (1.8%) 18 (2.1%)
 Unknown 22 47
Body mass index—no. (%)
 Underweight/normal (< 25) 75 (28.8%) 192 (26.9%)
 Overweight/obese (25 +) 185 (71.2%) 521 (73.1%)
 Unknown 41 207
Previous/actual smoker—No. (%) 51 (22.2%) 214 (29.2%)
 Unknown 71 188
Antiflu 2019 vaccination—No. (%) 54 (25.0%) 121 (20.3%)
 Unknown 85 325
Initial respiratory support—No. (%)
 Oxygen supplementation 146 (48.5%) 468 (50.9%)
 NIMV 106 (35.2%) 359 (39.0%)
 IMV 49 (16.3%) 93 (10.1%)
PaO2/FiO2 ratio—median (IQR) 136 (93,198) 154 (103,218)
PaO2/FiO2 ratio—No. (%)
  < 100 55 (32.4%) 129 (24.1%)
 101–200 76 (44.7%) 244 (45.5%)
 201–300 32 (18.8%) 116 (21.6%)
  > 300 7 (4.1%) 47 (8.8%)
 Missing or not tested 131 384
Comorbidities (mild or worse)—No. 
(%)
 Heart disease 62 (21.6%) 150 (18.1%)
 Hypertension 147 (51.2%) 389 (47.0%)
 Diabetes 34 (11.8%) 138 (16.7%)
 Unknown 14 93
Concurrent treatment, no. (%)
 Antiretroviral 180 (63.1%) 576 (67.6%)
 Hydroxy‑chloroquine 207 (72.6%) 651 (76.4%)
 Antibiotics 118 (41.4%) 443 (52.0%)
 Steroids 62 (21.8%) 296 (34.7%)
 LMW heparin 66 (23.2%) 175 (20.5%)
Table 1 (continued)
ITT Phase 2 ITT Validation
N = 301 N = 920
 Unknown 16 68
C‑reactive protein—median (IQR) 37.6 (14.7, 120.0) 36.3 (13.7, 137.0)
 Missing or not tested 181 255
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Table 2 Distribution of baseline characteristics of patients collected at registration by treatment administration
Phase 2 Validation
Treated (n = 180) Not treated (n = 121) P Treated (n = 528) Not treated (n = 360) P
Geographic area—no. (%)  < 0.001 0.30
 Lombardia 94 (52.2%) 42 (34.7%) 195 (36.9%) 140 (38.9%)
 Veneto 14 (7.8%) 51 (42.1%) 28 (5.3%) 12 (3.3%)
 Emilia Romagna 29 (16.1%) 8 (6.6%) 76 (14.4%) 65 (18.1%)
 Other Northern regions – – 51 (9.7%) 40 (11.1%)
 Center 23 (12.8%) 16 (13.2%) 107 (20.3%) 61 (16.9%)
 South and Islands 20 (11.1%) 4 (3.3%) 71 (13.4%) 42 (11.7%)
Age—no. (%) 0.04 0.22
  ≤ 60 79 (43.9%) 43 (35.5%) 209 (39.6%) 156 (43.3%)
 61–70 67 (37.2%) 40 (33.1%) 148 (28.0%) 107 (29.7%)
 71 + 34 (18.9%) 38 (31.4%) 171 (32.4%) 97 (26.9%)
Female sex—no. (%) 31 (17.2%) 28 (23.1%) 0.20 108 (20.5%) 85 (23.6%) 0.26
Ethnic group—no. (%) 0.42 0.1
 Caucasian 170 (97.1%) 101 (97.1%) 494 (97.4%) 333 (97.9%)
 Asiatic 1 (0.6%) 2 (1.9%) 2 (0.4%) 0 (0.0%)
 Other 4 (2.3%) 1 (1.0%) 11 (2.2%) 7 (2.1%)
 Unknown 5 17 21 20
Body Mass Index—no. (%) 0.06 0.74
 Underweight/normal 40 (24.7%) 35 (35.7%) 112 (27.1%) 73 (26.0%)
 Overweight/Obese 122 (75.3%) 63 (64.3%) 301 (72.9%) 208 (74.0%)
 Unknown 18 23 115 79
Previous/actual smoker—no. (%) 33 (22.4%) 18 (21.7%) 0.89 130 (30.2%) 79 (27.9%) 0.52
 Unknown 33 38 97 77
Antiflu 2019 vaccination—no. (%) 31 (21.5%) 23 (31.9%) 0.10 75 (21.8%) 44 (18.5%) 0.33
 Unknown 36 49 184 122
Initial respiratory support– no. (%) 0.003 < 0.001
 Oxygen supplement 73 (40.6%) 73 (60.3%) 223 (42.2%) 223 (61.9%)
 NIMV 74 (41.1%) 32 (26.4%) 238 (45.1%) 112 (31.1%)
 IMV 33 (18.3%) 16 (13.2%) 67 (12.7%) 25 (6.9%)
PaO2/FiO2 ratio– no. (%) 0.08 < 0.001
  ≤ 100 36 (33.6%) 19 (30.2%) 91 (25.9%) 30 (18.3%)
 101–200 53 (49.5%) 23 (36.5%) 170 (48.4%) 66 (40.2%)
 201–300 14 (13.1%) 18 (28.6%) 68 (19.4%) 44 (26.8%)
 > 300 4 (3.7%) 3 (4.8%) 22 (6.3%) 24 (14.6%)
 Unknown 73 58 177 196
Heart disease—no. (%) 31 (17.8%) 31 (27.4%) 0.053 99 (19.4%) 48 (15.6%) 0.17
 Unknown 6 8 18 53
Hypertension—no. (%) 92 (52.9%) 55 (48.7%) 0.49 242 (47.5%) 141 (45.9%) 0.67
 Unknown 6 8 18 53
Diabetes—no. (%) 23 (13.2%) 11 (9.7%) 0.37 84 (16.5%) 51 (16.6%) 0.96
 Unknown 6 8 18 53
Anti‑retroviral—no. (%) 112 (65.1%) 113 (60.2%) 0.40 342 (66.4%) 224 (69.4%) 0.38
 Unknown 8 8 13 37
Hydroxy‑chloroquine—no. (%) 130 (75.6%) 77 (68.1%) 0.17 395 (76.7%) 244 (75.5%) 0.70
 Unknown 8 8 13 37
Antibiotics—no. (%) 84 (48.8%) 34 (30.1%) 0.002 274 (53.2%) 163 (50.5%) 0.44
 Unknown 8 8 13 37
Steroids—no. (%) 41 (23.9%) 21 (18.6) 0.29 176 (34.2%) 115 (35.6%) 0.67
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lethality rates, consistently with preliminary findings of 
the Recovery trial. [14] Further, we did not find an inter-
action between the effect of tocilizumab and the concur-
rent administration of corticosteroids, consistent with 
another recent report. [15].
In the light of the large percentage of untreated sub-
jects (40%) and the selection bias of treating patients 
with worse prognosis, these results support using toci-
lizumab while waiting for the publication of results of 
the phase 3 clinical trials. To our knowledge, six ongoing 
randomised trials are comparing tocilizumab vs placebo 
(ChiCTR2000029765, NCT04320615, NCT04381936, 
EudraCT 2020-001408-41, NCT04330638, NCT2020-
001767-86) and another one is comparing immediate vs 
delayed tocilizumab (NCT04346355). However, some tri-
als have problems in reaching the planned sample size, 
and most of the trials on medical treatment of COVID-
19 are using non validated surrogate outcomes rather 
than mortality as primary end-point [16].
TOCIVID-19 is the largest completed prospective 
study on the effect of tocilizumab using mortality as 
primary end-point, among published or pre-published 
reports. Mostly, retrospective or observational data have 
been reported so far, not based on prospective hypoth-
esis testing, with prevalently positive results [17–32].
However, our study has several limitations that deserve 
discussion for a better interpretation of findings. The 
main limitation is the single-arm study design, which 
prevents definitive conclusions [33]. We did that because, 
in our opinion, a randomised controlled trial was unfea-
sible in the middle of March 2020 in Italy. Indeed, there 
was a tremendous pressure to have the drug available, 
due to a widespread media diffusion of positive expecta-
tions and the increasing number of patients hospitalized 
for the disease, as confirmed by the massive registration 
of centers when the study began. Physicians’ equipoise 
was poor, and obtaining a proper informed consent to 
randomization from patients was extremely difficult, 
because of clinical burden. Finally, developing a placebo 
was impossible, and, within a non-blinded study, the risk 
of cross-over from the control to the experimental arm 
would have been high, reducing the validity of the ran-
domised trial. Within this context, the problem of “learn-
ing while doing” was increased, and we thought that the 
single-arm design was the best trade-off between do-
something and learn-something [34].
A critical issue of the single-arm design was the defi-
nition of the null hypotheses to be tested. We amended 
them following the evolving information from the 
National Institute of Health when we were blind to out-
come data and in agreement with IDMC [10]. Yet, we 
cannot be sure that our assumptions are unbiased. A 
study with data on about 43.000 patients coming from 
three Italian regions, reports higher lethality at 14  days 
(22.0%) and lower at 30  days (27.6%) compared to 
TOCIVID-19 null hypotheses; assuming these estimates 
as a benchmark, our results would be still clinically sig-
nificant at both 14 and 30 days [35].
Difference of survival experience between the two 
cohorts was unexpected. However, due to the excep-
tional setting in which the study was conducted, the 
Table 2 (continued)
Phase 2 Validation
Treated (n = 180) Not treated (n = 121) P Treated (n = 528) Not treated (n = 360) P
 Unknown 8 8 13 37
LMW heparin—no. (%) 45 221 0.14 116 (22.5%) 57 (17.7%) 0.09
 Unknown 8 8 13 37
C‑reactive protein—median (IQR) 30 (13–116) 73 (17–122) 0.06 31 (14–132) 57 (14–144) 0.38
 Unknown 34 29 102 128
Table 3 Efficacy analysis
Phase 2 Validation
14 days intention‑to‑treat
No. of events/no. of patients at risk 55/299 101/884
Lethality rate, % (97.5% CI) 18.4% (13.6–24.0) 11.4% (9.1–14.0)
P value (P0 = 20%) 0.52  < 0.001
14 days modified intention‑to‑
treat
No. of events/no. of patients at risk 28/180 56/515
 Lethality rate, % (95% CI) 15.6% (10.6–21.7) 10.9% (8.3–13.9)
30 days intention‑to‑treat
No. of events/No. of patients at 
risk
67/299 158/858
 Lethality rate, % (97.5% CI) 22.4% (17.2–28.3) 18.4% (15.5–21.6)
 P value (P0 = 35%)  < 0.001  < 0.001
 Median time of death, days (IQR) 8 (4–14) 11 (4–18)
30 days modified intention‑to‑
treat
No. of events/no. of patients at risk 36/180 99/495
 Lethality rate, % (95% CI) 20.0% (14.4–26.6) 20.0% (16.6–23.8)
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Fig. 2 Estimated lethality rates at 14 and 30 days by baseline characteristics of patients in the phase 2 ITT population. Red dash lines represent 
lethality rates under null hypotheses
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validation cohort allowed the appreciation of the het-
erogeneity of the study population. Thus, combining 
cohorts in the multivariable evaluation seemed the 
most reasonable approach to explore prognostic factors 
while adjusting for the many confounding factors.
An operational problem of our study was the discrep-
ancy between timing of drug availability (notwithstand-
ing the commitment of the pharma company) and the 
extremely high request due to the rapid recruitment 
rate. Two contrasting biases followed in our study: 
the indication (selection) bias, when physicians opted 
for treating patients with worse prognosis, and the 
immortal time bias, when delay of treatment admin-
istration favored subjects surviving longer enough to 
receive the drug. As expected, the latter bias was par-
ticularly evident at 14-day analysis. To be conservative, 
we excluded from multivariable analyses all patients 
receiving the drug later than three days from registra-
tion, and adjusted for all available confounding factors, 
although some residual bias may still exist. Thus, find-
ings of the multivariable analyses are to be considered 
hypothesis-generating only.
Last, we had many missing data, for several reasons: 
massive involvement and stress of physicians in emer-
gency care; paucity or absence of data-managers; quar-
antine of paper charts; impracticality of peripheral 
monitoring; lack of training to the web platform; slow 
web connections for the study platform due to huge 
information loading volume. In agreement with IDMC, 
we reduced the problem by removing un-cooperative 
centers that provided baseline information for less than 
25% of patients; however, we cannot be confident that the 
remaining missing data are at random.
TOCIVID-19 also has some strengths. As mentioned 
above, it is the first academic trial promoted in Italy, the 
largest in terms of centers and patients (being available 
for the whole Italian territory), assessing a hard end-
point like mortality in a hypothesis-driven design, while 
off label use of the drug was increasing. [36] In addition, 
the internal validation, allowed by a companion prospec-
tive cohort, contributed to critical interpretation of the 
results. Further analyses will focus on secondary out-
comes (e.g. respiratory outcomes, predictive and prog-
nostic factors, epidemiology insights) and on a larger 
number of patients.
Conclusions
Although with limitations of a single-arm study, per-
formed in an extremely challenging time and environ-
ment, the present study supports the use of tocilizumab, 
even when corticosteroids are used, while waiting for 
publication of phase 3 results.
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